Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report), retaining the price target of ...
For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase ( ...
Tenaya plans to present data from its pediatric non-interventional natural history study, known as MyClimb, in the second ...
Tenaya Therapeutics (TNYA) provided an update on its clinical development programs and outlined its strategic priorities for 2025. Updates: ...
Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent ...
Background and aims Hypertrophic cardiomyopathy (HCM) has various aetiologies, including genetic conditions like Fabry ...
Women may be missing a diagnosis of a potentially deadly heart condition due to guidelines that don't account for natural differences in sex and body size.
Women may be missing a diagnosis of a potentially deadly heart condition due to guidelines that don't account for natural differences in sex and body size, according to a new study led by UCL ...
After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...
Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...